scispace - formally typeset
A

Augen A. Pioszak

Researcher at University of Oklahoma Health Sciences Center

Publications -  38
Citations -  1733

Augen A. Pioszak is an academic researcher from University of Oklahoma Health Sciences Center. The author has contributed to research in topics: Receptor & G protein-coupled receptor. The author has an hindex of 20, co-authored 35 publications receiving 1481 citations. Previous affiliations of Augen A. Pioszak include University of Michigan & Van Andel Institute.

Papers
More filters
Journal ArticleDOI

Molecular recognition of parathyroid hormone by its G protein-coupled receptor

TL;DR: A method for expression and purification of the extracellular domain (ECD) of human PTH1R engineered as a maltose-binding protein (MBP) fusion that readily crystallizes is presented, revealing critical insights into PTH actions and providing a rational template for drug design that targets this hormone signaling pathway.
Journal ArticleDOI

Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1.

TL;DR: Three crystal structures of the human CRFR1 ECD are presented, one in a ligand-free form and two in distinct CRF-bound states, providing a molecular framework for understanding peptide binding and specificity by the CRF receptors as a template for designing potent and selective CRFR 1 antagonists for therapeutic applications.
Journal ArticleDOI

Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles

TL;DR: The first peptide-bound structures of RAMP-GPCR complexes are discussed, which give insight into the molecular mechanisms that enable RAMPs to alter the pharmacology and signaling of GPCRs.
Journal ArticleDOI

Structural Basis for Parathyroid Hormone-related Protein Binding to the Parathyroid Hormone Receptor and Design of Conformation-selective Peptides

TL;DR: A molecular model is established for better understanding of how two biologically distinct ligands can act through a single receptor and provide a template for designing better PTH/PTHrP therapeutics.